Abstract
Mathematical modelling is important for better understanding of disease dynamics and developing strategies to manage rapidly spreading infectious diseases. In this work, we consider a mathematical model of COVID-19 transmission with double-dose vaccination strategy to control the disease. For the analytical analysis purpose we divided the model into two, model with vaccination and without vaccination. Analytical and numerical approach is employed to investigate the results. In the analytical study of the model we have shown the local and global stability of disease-free equilibrium, existence of the endemic equilibrium and its local stability, positivity of the solution, invariant region of the solution, transcritical bifurcation of equilibrium and sensitivity analysis of the model is conducted. From these analyses, for the full model (model with vaccination) we found that the disease-free equilibrium is globally asymptotically stable for Rv < 1 and is unstable for Rv > 1. A locally stable endemic equilibrium exists for Rv > 1, which shows the persistence of the disease if the reproduction parameter is greater than unity. The model is fitted to cumulative daily infected cases and vaccinated individuals data of Ethiopia from May 01, 2021 to January 31, 2022. The unknown parameters are estimated using the least square method with the MATLAB built-in function ‘lsqcurvefit’. The basic reproduction number, R0 and controlled reproduction number Rv are calculated to be R0 = 1.17 and Rv = 1.15 respectively. Finally, we performed different simulations using MATLAB. From the simulation results, we found that it is important to reduce the transmission rate, infectivity factor of asymptomatic cases and, increase the vaccination coverage and quarantine rate to control the disease transmission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Our World in Data
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Updates in Introduction, model formulation and conclusion sections
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
